Revenue rose by 4 % to EUR 2.47 billion, while gross profit increased by 5 % to EUR 634 million. Gross profit rose slightly to EUR 293 million, while EBITA decreased by 4 % to EUR 124 million. In the Americas, IMCD recorded a 6 % revenue increase to EUR 770 million and EBITA growth of 7 % to EUR 83 million. In Asia-Pacific, revenue grew slightly by 1 % to EUR 639 million, while gross profit increased more strongly by 7 % to EUR 150 million. EBITA rose by 5 % to EUR 86 million, supported by acquisitions such as YCAM (South Korea) and Daoqin (China) in personal care, pharmaceuticals and food ingredients.